Digestive and Liver Disease
Volume 42, Issue 9 , Pages 597-605 , September 2010

Familial pancreatic cancer in Italy. Risk assessment, screening programs and clinical approach: A position paper from the Italian Registry

  • Marco Del Chiaro

      Affiliations

    • Division of General and Transplant Surgery, Pisa University Hospital, Via Paradisa, 2, 56124 Cisanello, Pisa, Italy
    • Corresponding Author InformationCorresponding author. Tel.: +39 050996926.
    • ,
  • Alessandro Zerbi

      Affiliations

    • Pancreatic Surgery Section, Department of Surgery, IRCCS Istituto Clinico Humanitas, Rozzano, Milan, Italy
    • ,
  • Gabriele Capurso

      Affiliations

    • Digestive and Liver Disease Unit, University “La Sapienza”, Rome, Italy
    • ,
  • Giuseppe Zamboni

      Affiliations

    • Department of Pathology, University of Verona, Italy
    • ,
  • Patrick Maisonneuve

      Affiliations

    • European Institute of Oncology, Milan, Italy
    • ,
  • Silvano Presciuttini

      Affiliations

    • University of Pisa, Department of Biology, Italy
    • ,
  • Paolo Giorgio Arcidiacono

      Affiliations

    • Division of Gastroenterology and Gastrointestinal Endoscopy, Vita-Salute San Raffaele University, Milan, Italy
    • ,
  • Lucia Calculli

      Affiliations

    • Department of Radiology, University of Bologna, Italy
    • ,
  • Massimo Falconi

      Affiliations

    • Surgical and Gastroenterological Department, University of Verona, Italy

Received 7 April 2010 ,Accepted 22 April 2010.

References 

  1. Sperti C, Pasquali C, Piccoli A, Pedrazzoli S. Survival after resection for ductal adenocarcinoma of the pancreas. Br J Surg. 1996;83:625–631
  2. Zanetti R, Buiatti E, Federico M, Micheli A. Fatti e Cifre dei Tumori in Italia. 1a Edizione. Rome, Italy: Il Pensiero Scientifico Editore; 1998;pp. 9–29
  3. Del Chiaro M, Zerbi A, Falconi M, et al. Cancer risk among the relatives of patients with pancreatic ductal adenocarcinoma. Pancreatology. 2007;7:459–469
  4. Iodice S, Gandini S, Maisonneuve P, Lowenfels AB. Tobacco and the risk of pancreatic cancer: a review and meta-analysis. Langebecks Arch Surg. 2008;393:535–545
  5. Mulder I, Hoogenveen RT, van Genugten ML. Smoking cessation would substantially reduce the future incidence of pancreatic cancer in the European Union. Eur J Gastroenterol Hepatol. 2002;14:1343–1353
  6. McWilliams RR, Bamlet WR, Rabe KG, et al. Association of family history of specific cancers with a younger age of onset of pancreatic adenocarcinoma. Clin Gastroenterol Hepatol. 2006;4:1143–1147
  7. Brand RE, Greer JB, Zolotarevsky E, et al. Pancreatic Cancer Patients Who Smoke and Drink are Diagnosed at Younger Ages. Clin Gastroenterol Hepatol. 2009;[Epub ahead of print] PubMed PMID: 19560558
  8. Rulyak SJ, Lowenfels AB, Maisonneuve P, Brentnall TA. Risk factors for the development of pancreatic cancer in familial pancreatic cancer kindreds. Gastroenterology. 2003;124:1292–1299
  9. Howes N, Lerch MM, Greenhalf W, et al. Clinical and genetic characteristics of hereditary pancreatitis in Europe. Clin Gastroenterol Hepatol. 2004;2:252–261
  10. Talamini G, Falconi M, Bassi C, et al. Incidence of cancer in the course of chronic pancreatitis. Am J Gastroenterol. 1999;92:1253–1260
  11. Hassan MM, Bondy ML, Wolff RA, et al. Risk factors for pancreatic cancer: case-control study. Am J Gastroenterol. 2007;102:1–12
  12. Giovannucci E, Michaud D. The role of obesity and related metabolic disturbances in cancers of the colon, prostate, and pancreas. Gastroenterology. 2007;132:2208–2225
  13. Larsson SC, Orsini N, Wolk A. Body mass index and pancreatic cancer risk: a meta-analysis of prospective studies. Int J Cancer. 2007;120:1993–1998
  14. Berrington de Gonzalez A, Sweetland S, Spencer E. A meta-analysis of obesity and the risk of pancreatic caner. Br J Cancer. 2003;89:519–523
  15. Pezzilli R, Morselli-Labate AM, Migliori M, et al. Obesity and the risk of pancreatic cancer: an Italian multicenter study. Pancreas. 2005;31:221–224
  16. Renehan AG, Tyson M, Egger M, et al. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008;371:569–578
  17. Li D, Morris JS, Liu J, et al. Body mass index and risk, age of onset, and survival in patients with pancreatic cancer. J Am Med Assoc. 2009;301:2553–2562
  18. Jiao L, Silverman DT, Schairer C, et al. Alcohol Use and Risk of Pancreatic Cancer. The NIH-AARP Diet and Health Study. Am J Epidemiol. 2009;
  19. Genkinger JM, Spiegelman D, Anderson KE, et al. Alcohol intake and pancreatic cancer risk: a pooled analysis of fourteen cohort studies. Cancer Epidemiol Biomarkers Prev. 2009;18:765–776
  20. Anderson KE, Sinha R, Kulldorff M, et al. Meat intake and cooking techniques: associations with pancreatic cancer. Mutat Res. 2002;506/507:225–231
  21. Michaud DS, Giovannucci E, Willett WC, et al. Dietary meat, dairy products, fat, and cholesterol and pancreatic cancer risk in a prospective study. Am J Epidemiol. 2003;157:1115–1125
  22. Jiao L, Mitrou PN, Reedy J, et al. A combined healthy lifestyle score and risk of pancreatic cancer in a large cohort study. Arch Intern Med. 2009;169:764–770
  23. Stevens RJ, Roddam AW, Beral V. Pancreatic cancer in type 1 and young-onset diabetes: systematic review and meta-analysis. Br J Cancer. 2007;96:507–509
  24. Huxley R, Ansare-Moghaddam A, Berrington de Gonzalez A, et al. Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br J Cancer. 2005;92:2076–2083
  25. Pannala R, Basu A, Petersen GM, Chari ST. New-onset diabetes: a potential clue to the early diagnosis of pancreatic cancer. Lancet Oncol. 2009;10:88–95
  26. Li D, Yeung SC, Hassan MM, Konopleva M, Abbruzzese JL. Antidiabetic therapies affect risk of pancreatic cancer. Gastroenterology. 2009;[Epub ahead of print]
  27. McKay CJ, Glen P, McMillan DC. Chronic inflammation and pancreatic cancer. Best Pract Res Clin Gastroenterol. 2008;22:65–73
  28. Ojajärvi IA, Partanen TJ, Ahlbom A, et al. Occupational exposures and pancreatic cancer: a meta-analysis. Occup Environ Med. 2000;57:316–324
  29. Stolzenberg-Solomon RZ, Blaser MJ, Limburg PJ, et al. Helicobacter pylori seropositivity as a risk factor for pancreatic cancer. J Natl Cancer Inst. 2001;93:937–941
  30. de Martel C, Llosa AE, Friedmana GD, et al. Helicobacter pylori infection and development of pancreatic cancer. Cancer Epidemiol Biomarkers Prev. 2008;17:1188–1194
  31. Luo J, Nordenvall C, Nyrén O, et al. The risk of pancreatic cancer in patients with gastric or duodenal ulcer disease. Int J Cancer. 2007;120:368–377
  32. Capurso G, Delle Fave G, Lemoine N. Re: Etiology of pancreatic cancer, with a hypothesis concerning the role of N-nitroso compounds and excess gastric acidity. J Natl Cancer Inst. 2004;96:75
  33. Gandini S, Lowenfels AB, Jaffee EM, et al. Allergies and the risk of pancreatic cancer: a meta-analysis with review of epidemiology and biological mechanisms. Cancer Epidemiol Biomarkers Prev. 2005;14:1908–1916
  34. Bjelakovic G, Nikolova D, Simonetti RG, Gluud C. Antioxidant supplements for prevention of gastrointestinal cancers: a systematic review and meta-analysis. Lancet. 2004;364:1219–1228
  35. Larsson SC, Giovannucci E, Wolk A. Folate intake, MTHFR polymorphisms, and risk of esophageal, gastric, and pancreatic cancer: a meta-analysis. Gastroenterology. 2006;131:1271–1283
  36. Bonovas S, Filioussi K, Sitaras NM. Statins are not associated with a reduced risk of pancreatic cancer at the population level, when taken at low doses for managing hypercholesterolemia: evidence from a meta-analysis of 12 studies. Am J Gastroenterol. 2008;103:2646–2651
  37. Capurso G, Schünemann HJ, Terrenato I, et al. Meta-analysis: the use of non-steroidal anti-inflammatory drugs and pancreatic cancer risk for different exposure categories. Aliment Pharmacol Ther. 2007;26:1089–1099
  38. Klein AP, Brune KA, Petersen GM, et al. Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds. Cancer Res. 2004;64:2634–2638
  39. Evans JP, Burke W, Chen R, et al. Familial pancreatic adenocarcinoma: association with diabetes and early molecular diagnosis. J Med Genet. 1995;32:330–335
  40. Brentnall TA, Bronner MP, Byrd DR, Haggitt RC, Kimmey MB. Early diagnosis and treatment of pancreatic dysplasia in patients with a family history of pancreatic cancer. Ann Intern Med. 1999;131:247–255
  41. Naderi A, Couch FJ. BRCA2 and pancreatic cancer. Int J Gastrointest Cancer. 2002;31:99–106
  42. Thompson D, Easton DF. Breast Cancer Linkage Consortium. Cancer incidence in BRCA1 mutation carriers. J Natl Cancer Inst. 2002;94:1358–1365
  43. Lynch HT, Voorhees GJ, Lanspa SJ, McGreevy PS, Lynch JF. Pancreatic carcinoma and hereditary nonpolyposis colorectal cancer: a family study. Br J Cancer. 1985;52:271–273
  44. Aarnio M, Sankila R, Pukkala E, et al. Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer. 1999;81:214–218
  45. Watson P, Vasen HF, Mecklin JP, et al. The risk of extra-colonic, extra-endometrial cancer in the Lynch syndrome. Int J Cancer. 2008;123:444–449
  46. Elkharwily A, Gottlieb K. The pancreas in familial adenomatous polyposis. JOP. 2008;9:9–18
  47. Giardiello FM, Offerhaus GJ, Lee DH, et al. Increased risk of thyroid and pancreatic carcinoma in familial adenomatous polyposis. Gut. 1993;34:1394–1396
  48. Maisonneuve P, Marshall BC, Lowenfels AB. Risk of pancreatic cancer in patients with cystic fibrosis. Gut. 2007;56:1327–1328
  49. Lowenfels AB, Maisonneuve P, DiMagno EP, et al. Hereditary pancreatitis and the risk of pancreatic cancer. International Hereditary Pancreatitis Study Group. J Natl Cancer Inst. 1997;89:442–446
  50. Howes N, Lerch MM, Greenhalf W, et al. European Registry of Hereditary Pancreatitis and Pancreatic Cancer (EUROPAC). Clinical and genetic characteristics of hereditary pancreatitis in Europe. Clin Gastroenterol Hepatol. 2004;2:252–261
  51. Vasen HF, Gruis NA, Frants RR, van Der Velden PA, Hille ET, Bergman W. Risk of developing pancreatic cancer in families with familial atypical multiple mole melanoma associated with a specific 19 deletion of p16 (p16-Leiden). Int J Cancer. 2000;87:809–811
  52. Borg A, Sandberg T, Nilsson K, et al. High frequency of multiple melanomas and breast and pancreas carcinomas in CDKN2A mutation-positive melanoma families. J Natl Cancer Inst. 2000;92:1260–1266
  53. Giardiello FM, Brensinger JD, Tersmette AC, et al. Very high-risk of cancer in familial Peutz–Jeghers syndrome. Gastroenterology. 2000;119:1447–1453
  54. van der Heijden MS, Yeo CJ, Hruban RH, Kern SE. Fanconi anemia gene mutations in young-onset pancreatic cancer. Cancer Res. 2003;63:2585–2588
  55. Couch FJ, Johnson MR, Rabe K, et al. Germ line Fanconi anemia complementation group C mutations and pancreatic cancer. Cancer Res. 2005;65:383–386
  56. Geoffroy-Perez B, Janin N, Ossian K, et al. Cancer risk in heterozygotes for ataxia-telangiectasia. Int J Cancer. 2001;93:288–293
  57. Li FP, Fraumeni JF, Mulvihill JJ, et al. A cancer family syndrome in twenty-four kindreds. Cancer Res. 1988;48:5358–5362
  58. Hammel PR, Vilgrain V, Terris B, et al. Pancreatic involvement in von Hippel-Lindau disease. The Groupe Francophone d’Etude de la Maladie de von Hippel-Lindau. Gastroenterology. 2000;119:1087–1095
  59. Alexakis N, Connor S, Ghaneh P, et al. Hereditary pancreatic endocrine tumours. Pancreatology. 2004;4:417–433
  60. Raimondi S, Maisonneuve P, Löhr JM, Lowenfels AB. Early onset pancreatic cancer: evidence of a major role for smoking and genetic factors. Cancer Epidemiol Biomarkers Prev. 2007;16:1894–1897
  61. Lowenfels AB, Maisonneuve P, Whitcomb DC, Lerch MM, DiMagno EP. Cigarette smoking as a risk factor for pancreatic cancer in patients with hereditary pancreatitis. J Am Med Assoc. 2001;286:169–170
  62. Wang W, Chen S, Brune KA, Hruban RH, Parmigiani G, Klein AP. PancPRO: risk assessment for individuals with a family history of pancreatic cancer. J Clin Oncol. 2007;25:1417–1422
  63. Hruban RH, Pitman MB, Klimstra DS. Tumors of the pancreas. AFIP Atlas of tumor pathology, 6 vol.. Washington, DC: American Registry of Pathology, Armed Forces Institute of Pathology; 2007;
  64. Hruban RH, Takaori K, Canto M, et al. Clinical importance of precursor lesions in the pancreas. J Hepatobiliary Pancreat Surg. 2007;14:255–263
  65. Hruban RH, Takaori K, Klimstra DS, et al. An illustrated consensus on the classification of pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms. Am J Surg Pathol. 2004;28:977–987
  66. Kim GE, Bae HI, Park HU, et al. Aberrant expression of MUC5AC and MUC6 gastric mucins and sialyl Tn antigen in intraepithelial neoplasms of the pancreas. Gastroenterology. 2002;123:1052–1060
  67. Prasad NB, Biankin AV, Fukushima N, et al. Gene expression profiles in pancreatic intraepithelial neoplasia reflect the effects of Hedgehog signaling on pancreatic ductal epithelial cells. Cancer Res. 2005;65:1619–1626
  68. Maitra A, Adsay NV, Argani P, et al. Multicomponent analysis of the pancreatic adenocarcinoma progression model using a pancreatic intraepithelial neoplasia tissue microarray. Mod Pathol. 2003;16:902–912
  69. Maitra A, Ashfaq R, Gunn CR, et al. Cyclooxygenase 2 expression in pancreatic adenocarcinoma and pancreatic intraepithelial neoplasia: an immunohistochemical analysis with automated cellular imaging. Am J Clin Pathol. 2002;118:194–201
  70. Cubilla AL, Fitzgerald PJ. Morphological lesions associated with human primary invasive nonendocrine pancreas cancer. Cancer Res. 1976;36:2690–2698
  71. Andea A, Sarkar F, Adsay VN. Clinicopathological correlates of pancreatic intraepithelial neoplasia: a comparative analysis of 82 cases with and 152 cases without pancreatic ductal adenocarcinoma. Mod Pathol. 2003;16:996–1006
  72. Brune K, Abe T, Canto M, et al. Multifocal neoplastic precursor lesions associated with lobular atrophy of the pancreas in patients having a strong family history of pancreatic cancer. Am J Surg Pathol. 2006;30:1067–1076
  73. Luttges J, Zamboni G, Longnecker D, Kloppel G. The immunohistochemical mucin expression pattern distinguishes different types of intraductal papillary mucinous neoplasms of the pancreas and determines their relationship to mucinous noncystic carcinoma and ductal adenocarcinoma. Am J Surg Pathol. 2001;25:942–948
  74. Adsay NV, Merati K, Basturk O, et al. Pathologically and biologically distinct types of epithelium in intraductal papillary mucinous neoplasms: delineation of an “intestinal” pathway of carcinogenesis in the pancreas. Am J Surg Pathol. 2004;28:839–848
  75. Yamaguchi T, Baba T, Ishihara T, et al. Long-term follow-up of intraductal papillary mucinous neoplasm of the pancreas with ultrasonography. Clin Gastroenterol Hepatol. 2005;3:1136–1143
  76. Canto MI, Goggins M, Hruban RH, et al. Screening for early pancreatic neoplasia in high-risk individuals: a prospective controlled study. Clin Gastroenterol Hepatol. 2006;4:766–781[quiz 665]
  77. Su GH, Hruban RH, Bansal RK, et al. Germline and somatic mutations of the STK11/LKB1 Peutz–Jeghers gene in pancreatic and biliary cancers. Am J Pathol. 1999;154:1835–1840
  78. Maire F, Hammel P, Terris B, et al. Intraductal papillary and mucinous pancreatic tumour: a new extracolonic tumour in familial adenomatous polyposis. Gut. 2002;51:446–449
  79. Zamboni G, Scarpa A, Bogina G, et al. Mucinous cystic tumors of the pancreas: clinicopathological features, prognosis, and relationship to other mucinous cystic tumors. Am J Surg Pathol. 1999;23:410–422
  80. Zamboni G, Klöppel G, Hruban R, Longnecker D, Adler G. Mucinous cystic neoplasms of the pancreas. Lyon: IARC Press; 2000;pp. 234–236
  81. Fukushima N, Sato N, Prasad N, Leach SD, Hruban RH, Goggins M. Characterization of gene expression in mucinous cystic neoplasms of the pancreas using oligonucleotide microarrays. Oncogene. 2004;23:9042–9051
  82. Iacobuzio-Donahue CA, Wilentz RE, Argani P, et al. Dpc4 protein in mucinous cystic neoplasms of the pancreas: frequent loss of expression in invasive carcinomas suggests a role in genetic progression. Am J Surg Pathol. 2000;24:1544–1548
  83. Miller FH, Rini NJ, Keppke AL. MRI of adenocarcinoma of the pancreas. AJR Am J Roentgenol. 2006;187:W365–W374
  84. Bipat S, Phoa SS, van Delden OM, et al. Ultrasonography, computed tomography and magnetic resonance imaging for diagnosis and determining resectability of pancreatic adenocarcinoma: a meta-analysis. J Comput Assist Tomogr. 2005;29:438–445
  85. Ichikawa T, Peterson M, Federle M, et al. Islet cell tumor of pancreas: biphasic CT versus MR imaging in tumor detection. Radiology. 2000;216:163–171
  86. Nishiharu T, Yamashita Y, Abe Y, et al. Local extension of pancreatic carcinoma: assessment with thin-section helical CT versus with breath-hold fast MR imaging-ROC analysis. Radiology. 1999;212:445–452
  87. Sahani DV, Shah ZK, Catalano OA, Boland GW, Brugge WR. Radiology of pancreatic adenocarcinoma: current status of imaging. J Gastroenterol Hepatol. 2008;23:23–33
  88. Mertz H, Sechopoulos P, Delbeke D, Leach SD. EUS, PET, and CT scanning for evaluation of pancreatic adenocarcinomas. Gastrointest Endosc. 2000;52:367–371
  89. Legmann P, Vignaux O, Dousset B, Baraza AJ, Palazzo L, Dumontier I, et al. Pancreatic tumors: comparison of dual-phase helical CT and endoscopic sonographic. Am J Roentgenol. 1998;170:1315–1322
  90. Raut CP, Grau AM, Staerkel GA, et al. Diagnostic accuracy of endoscopic ultrasound-guided fine-needle aspiration in patients with presumed pancreatic cancer. J Gastrointest Surg. 2003;7:118–128
  91. Ariyama J, Suyama M, Satoh K, Sai J. Imaging of small pancreatic ductal adenocarcinoma. Pancreas. 1998;16:396–401
  92. Hunt GC, Faigel DO. Assessment of EUS for diagnosing, staging, and determining resectability of pancreatic cancer: a review. Gastrointest Endosc. 2002;55:232–237
  93. DeWitt J, Devereaux B, Chriswell M, et al. Comparison of endoscopic ultrasonography and multidetector computer tomography for detecting and staging pancreatic cancer. Ann Intern Med. 2004;141:753–763
  94. Agarwal B, Abu-Hamda E, Molke KL, Correa AM, HO L. Endoscopic ultrasound-guided fine needle aspiration and multidetector spiral CT in the diagnosis of pancreatic cancer. Am J Gastroenterol. 2004;99:844–850
  95. Chang KJ, Nguyen P, Erickson RA, Durbin TE, Katz KD. The clinical utility of endoscopic ultrasound-guided fine-needle aspiration in the diagnosis and staging of pancreatic carcinoma. Gastrointest Endosc. 1997;45:387–393
  96. Farrow B, Sugiyama Y, Chen A, Uffort E, Nealon W, Evers BM. Inflammatory mechanisms contributing to pancreatic cancer development. Ann Surg. 2004;239:763–771
  97. Rulyak SJ, Kimmey MB, Veenstra DL, Brentnall TA. Cost-effectiveness of pancreatic cancer screening in familial pancreatic cancer kindreds. Gastrointest Endosc. 2003;57:23–29
  98. Adler DG, Jacobson BC, Davila RE, et al. Faigel DO ASGE guideline: complications of EUS. Gastrointest Endosc. 2005;61:8–12
  99. Fernández-Esparrach G, Ginès A, García P, et al. Incidence and clinical significance of hyperamylasemia after endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) of pancreatic lesions: a prospective and controlled study. Endoscopy. 2007;39:720–724
  100. Gress F, Michael H, Gelrud D, et al. EUS guided fine-needle aspiration of the pancreas: evaluation of pancreatitis as a complication. Gastrointest Endosc. 2002;56:864–867
  101. O’Toole D, Palazzo L, Arotcarena R, et al. Assessment of complications of EUS-guided fine-needle aspiration. Gastrointest Endosc. 2001;53:470–474
  102. Al-Haddad M, Wallace MB, Woodward TA, et al. The safety of fine-needle aspiration guided by endoscopic ultrasound: a prospective study. Endoscopy. 2008;40:204–208
  103. Affi A, Vazquez-Sequeiros E, Norton I, Clain J, Wiersema M. Acute extraluminal hemorrhage associated with EUS-guided fine needle aspiration: Frequency and clinical significance. Gastrointest Endosc. 2001;53:221–225
  104. Eloubeidi M, Tamhane A, Varadarajulu S, Wilcox C. Frequency of major complications after EUS-guided FNA of solid pancreatic masses: a prospective evaluation. Gastrointest Endosc. 2006;63:622–629
  105. Eloubeidi MA, Chen VK, Eltoum IA, et al. Endoscopic ultrasound-guided fine needle aspiration biopsy of patients with suspected pancreatic cancer: diagnostic accuracy and acute and 30-day complications. Am J Gastroenterol. 2003;98:2663–2668
  106. Varadarajulu S, Eloubeidi MA. Frequency and significance of acute intracystic hemorrhage during EUS-FNA of cystic lesions of the pancreas. Gastrointest Endosc. 2004;60:631–635
  107. Levy MJ, Norton ID, Wiersema MJ, et al. Prospective risk assessment of bacteremia and other infectious complications in patients undergoing EUS-guided FNA. Gastrointest Endosc. 2003;57:672–678
  108. Yeo CJ, Cameron JL, Lillemoe KD, et al. Pancreaticoduodenectomy for cancer of the head of the pancreas, 201 patients. Ann Surg. 1995;221:721–731
  109. Malesci A, Montorsi M, Mariani A, et al. Clinical utility of the serum CA 19-9 test for diagnosing pancreatic carcinoma in symptomatic patients: a prospective study. Pancreas. 1992;7:497–502
  110. Kimmey MB, Brentnall TA, Bronner MP, et al. Endoscopic ultrasound screening for familial pancreatic cancer. Gastrointest Endosc. 2002;56:S82–S86
  111. Canto MI, Goggins M, Yeo CJ, et al. Screening for pancreatic neoplasia in highrisk individuals: an EUS-based approach. Clin Gastroenterol Hepatol. 2004;2:606–621
  112. Jorgensen MT, Mortensen MB, Gerdes AM, Schaffalitzky De Muckadell OB. Familial pancreatic cancer. Scand J Gastroenterol. 2008;43:387–397
  113. Brand RE, Lerch MM, Rubinstein WS, et al. Advances in Counseling and Surveillance of Patients at Risk for Pancreatic Cancer. Gut. 2007;56:1460–1469
  114. McFaul C, Greenhalf W, Earl J, et al. Anticipation in familial pancreatic cancer. Gut. 2006;55:252–258
  115. Singh M, Maitra A. Precursor lesions of pancreatic cancer: molecular pathology and clinical implications. Pancreatology. 2007;7:9–19Epub 2007 April 18
  116. White R, D’Angelica M, Katabi N, et al. Fate of the remnant pancreas after resection of noninvasive intraductal papillary mucinous neoplasm. J Am Coll Surg. 2007;204:987–993discussion 993–5. Epub 2007 Mar 27
  117. Kekis PB, Friess H, Kleeff J, Büchler MW. Timing and extent of surgical intervention in patients from hereditary pancreatic cancer kindreds. Pancreatology. 2001;1:525–530
  118. Rulyak SJ, Brentnall TA. Inherited pancreatic cancer: surveillance and treatment strategies for affected families. Pancreatology. 2001;1:477–485[review]
  119. Davis B, Lowy AM. Surgical management of hereditary pancreatic cancer. Med Clin North Am. 2000;84:749–759[review. Department of Surgery, University of Cincinnati College of Medicine, OH, USA]
  120. Charpentier KP, Brentnall TA, Bronner MP, Byrd D, Marsh C. A new indication for pancreas transplantation: high grade pancreatic dysplasia. Clin Transplant. 2004;18:105–107
  121. Steinberg WM, Barkin JS, Bradley EL, et al. Should patients with a strong family history of pancreatic cancer be screened on a periodic basis for cancer of the pancreas?. Pancreas. 2009;38:e137–e150
  122. Partelli S, Castillo CF, Bassi C, et al. Invasive intraductal papillary mucinous carcinomas of the pancreas: predictors of survival and the role of lymph node ratio. Ann Surg. 2010;251:477–482

PII: S1590-8658(10)00163-5

doi: 10.1016/j.dld.2010.04.016

Digestive and Liver Disease
Volume 42, Issue 9 , Pages 597-605 , September 2010

Article Tools